BRPI0918472A2 - composto 2,4-diaminopirimidina - Google Patents

composto 2,4-diaminopirimidina

Info

Publication number
BRPI0918472A2
BRPI0918472A2 BRPI0918472A BRPI0918472A BRPI0918472A2 BR PI0918472 A2 BRPI0918472 A2 BR PI0918472A2 BR PI0918472 A BRPI0918472 A BR PI0918472A BR PI0918472 A BRPI0918472 A BR PI0918472A BR PI0918472 A2 BRPI0918472 A2 BR PI0918472A2
Authority
BR
Brazil
Prior art keywords
diaminopyrimidine compound
diaminopyrimidine
compound
Prior art date
Application number
BRPI0918472A
Other languages
English (en)
Inventor
Akira Tanaka
Jun Maeda
Koichiro Mukoyoshi
Noboru Chida
Shigeki Kunikawa
Shinya Nagashima
Yuji Takasuna
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI0918472A2 publication Critical patent/BRPI0918472A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BRPI0918472A 2008-09-01 2009-08-31 composto 2,4-diaminopirimidina BRPI0918472A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008223323 2008-09-01
JP2009121482 2009-05-20
PCT/JP2009/065149 WO2010024430A1 (ja) 2008-09-01 2009-08-31 2,4-ジアミノピリミジン化合物

Publications (1)

Publication Number Publication Date
BRPI0918472A2 true BRPI0918472A2 (pt) 2015-12-01

Family

ID=41721589

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918472A BRPI0918472A2 (pt) 2008-09-01 2009-08-31 composto 2,4-diaminopirimidina

Country Status (10)

Country Link
US (1) US20110159019A1 (pt)
EP (1) EP2325175A4 (pt)
JP (1) JP5644499B2 (pt)
KR (1) KR20110049902A (pt)
CN (1) CN102137848A (pt)
BR (1) BRPI0918472A2 (pt)
CA (1) CA2735730A1 (pt)
MX (1) MX2011002306A (pt)
TW (1) TW201014832A (pt)
WO (1) WO2010024430A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012148977A (ja) * 2009-05-20 2012-08-09 Astellas Pharma Inc アミノシクロヘキシルアルキル基を有する２，４−ジアミノピリミジン化合物
JP5686413B2 (ja) * 2009-12-22 2015-03-18 塩野義製薬株式会社 アダマンタンアミン誘導体
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
ES2577829T3 (es) 2010-06-04 2016-07-19 F. Hoffmann-La Roche Ag Derivados de aminopirimidina como moduladores de la LRRK2
JP5812295B2 (ja) 2010-08-09 2015-11-11 塩野義製薬株式会社 アミノアダマンタンカルバメート誘導体の製造方法
JP2012067033A (ja) * 2010-09-22 2012-04-05 Kuraray Co Ltd アミノメチルピリジン誘導体の製造方法
WO2012059932A1 (en) * 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
HUE037844T2 (hu) 2010-11-10 2018-09-28 Genentech Inc Pirazol-aminopirimidin-származékok mint LRRK2 modulátorok
SG10201702654VA (en) 2011-04-22 2017-06-29 Signal Pharm Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
AU2016244228B2 (en) * 2011-04-22 2019-02-21 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
EP2760843B1 (en) * 2011-09-26 2016-03-02 Bristol-Myers Squibb Company Selective nr2b antagonists
US8722670B2 (en) 2011-09-30 2014-05-13 Bristol-Myers Squibb Company Selective NR2B antagonists
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
SG11201604821YA (en) * 2013-12-20 2016-07-28 Signal Pharm Llc Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
MX2017007883A (es) 2014-12-16 2017-09-05 Signal Pharm Llc Formulaciones de 2-(ter-butilamino)-4-((1r,3r,4r)-3-hdroxi-4-metil ciclohexilamino)-pirimidina-5-carboxamida.
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557A4 (en) 2015-01-29 2018-06-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2017019487A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
KR20180069005A (ko) 2015-10-26 2018-06-22 바이엘 크롭사이언스 악티엔게젤샤프트 농약으로서의 융합된 비사이클릭 헤테로사이클 유도체
WO2020173861A1 (de) 2019-02-26 2020-09-03 Bayer Aktiengesellschaft Kondensierte bicyclische heterocyclen-derivate als schädlingsbekämpfungsmittel
US20230060425A1 (en) 2019-02-26 2023-03-02 Bayer Aktiengesellschaft Fused bicyclic heterocycle derivatives as pesticides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
EP1392662B1 (de) * 2001-05-29 2009-01-07 Bayer Schering Pharma Aktiengesellschaft Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
CA2463989C (en) * 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
NZ539823A (en) * 2002-11-28 2008-04-30 Schering Aktiengessellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
AU2003289330A1 (en) 2002-12-13 2004-07-09 Kyowa Hakko Kogyo Co., Ltd. Preventives and/or remedies for central diseases
WO2004067516A1 (en) * 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
EP1763514A2 (en) * 2004-05-18 2007-03-21 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
JP2008505910A (ja) 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
EP1966163A1 (en) * 2005-12-21 2008-09-10 Boehringer Ingelheim International GmbH Pyrimidine derivatives useful as inhibitors of pkc-theta
EP2183225A1 (en) * 2007-07-17 2010-05-12 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
EP2387565B1 (en) * 2009-01-14 2016-12-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders

Also Published As

Publication number Publication date
WO2010024430A1 (ja) 2010-03-04
JPWO2010024430A1 (ja) 2012-01-26
MX2011002306A (es) 2011-05-25
TW201014832A (en) 2010-04-16
CN102137848A (zh) 2011-07-27
US20110159019A1 (en) 2011-06-30
EP2325175A4 (en) 2012-03-21
JP5644499B2 (ja) 2014-12-24
CA2735730A1 (en) 2010-03-04
EP2325175A1 (en) 2011-05-25
KR20110049902A (ko) 2011-05-12

Similar Documents

Publication Publication Date Title
BRPI0918472A2 (pt) composto 2,4-diaminopirimidina
NO2021006I1 (no) Quofenix, delafloksacin
BRPI0923786A2 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos
ATE555107T1 (de) 2-aza-bicyclo-ä2,2,1-üheptan-derivate
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
BRPI0815717A2 (pt) Compostos de imidazopirazina.
BRPI0813235A2 (pt) Combinação anti-helmíntica.
BRPI0907563A2 (pt) Derivados de 4,5-di-hidro-xazol-2-il amina
BRPI0922904A2 (pt) "compostos"
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
UY33125A (es) Diaza-espiro-[5,5]-undecanos
BRPI0918602A2 (pt) composto (i)
BRPI0923048A2 (pt) "composto de aminopirazol".
BRPI0912716A2 (pt) composto.
BRPI0923592A2 (pt) composto
IT1393413B1 (it) Composizione pesticida.
FR2932490B1 (fr) Composition polyamide.
BRPI0923067A2 (pt) "anodo capacitor".
BRPI0916395A2 (pt) compostos de 1,6-di-hidro-2h-3-oxa-6-aza-as-indaceno
FR2923713B1 (fr) Composition reductrice epaissie.
IT1396642B1 (it) Statore.
BRPI0913805A2 (pt) composto
IT1393582B1 (it) Composizione pesticida.
MA30860B1 (fr) Myrtillier denomme "c97-390"
FR2932857B1 (fr) Agrafe.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.